Google DeepMind, together with Isomorphic Labs, has introduced a new version of its AlphaFold AI technology, which helps scientists understand the behavior of the microscopic mechanisms that drive the cells in the human body. Launched in 2018, the earlier version of AlphaFold was released in 2023 for protein study.

AlphaFold's primary function is to study the twisting and folding process of proteins and their interaction with other human cells. The new version, AlphaFold3, is reported to have the additional feature of predicting the behavior of other microscopic biological mechanisms, including DNA and RNA.

Isomorphic Labs, a subsidiary of Alphabet, is a UK-based company that aims to enhance the traditional drug discovery process through the application of AI. The company is currently building on Google DeepMind’s AI research and collaborating with pharmaceutical companies, including Eli Lilly and Novartis, to advance its AI-driven drug discovery efforts.